Kynurenine Pathway Metabolites in Humans: Disease and Healthy States

Tryptophan is an essential amino acid that can be metabolised through different pathways, a major route being the kynurenine pathway. The first enzyme of the pathway, indoleamine-2,3-dioxygenase, is strongly stimulated by inflammatory molecules, particularly interferon gamma. Thus, the kynurenine pathway is often systematically up-regulated when the immune response is activated. The biological significance is that 1) the depletion of tryptophan and generation of kynurenines play a key modulatory role in the immune response; and 2) some of the kynurenines, such as quinolinic acid, 3-hydroxykynurenine and kynurenic acid, are neuroactive. The kynurenine pathway has been demonstrated to be involved in many diseases and disorders, including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, AIDS dementia complex, malaria, cancer, depression and schizophrenia, where imbalances in tryptophan and kynurenines have been found. This review compiles most of these studies and provides an overview of how the kynurenine pathway might be contributing to disease development, and the concentrations of tryptophan and kynurenines in the serum, cerebrospinal fluid and brain tissues in control and patient subjects.

[1]  V. Meininger,et al.  The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis , 2010, Neurotoxicity Research.

[2]  M. Cohen,et al.  [Depression in multiple sclerosis]. , 2009, Revue neurologique.

[3]  O. Hayaishi,et al.  Specific induction of pulmonary indoleamine 2,3-dioxygenase by bacterial lipopolysaccharide. , 2008, Ciba Foundation symposium.

[4]  C. García-Girón,et al.  Effect of 3-hydroxyanthranilic acid in the immunosuppressive molecules indoleamine dioxygenase and HLA-G in macrophages. , 2008, Immunology letters.

[5]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[6]  B. Brew,et al.  Effect of quinolinic acid on gene expression in human astrocytes: Implications for Alzheimer's disease , 2007 .

[7]  B. Brew,et al.  Mass spectrometric detection of quinolinic acid in microdissected Alzheimer's disease plaques , 2007 .

[8]  A. Chiarugi,et al.  Kynurenic acid actions in brain and periphery , 2007 .

[9]  B. Brew,et al.  Characterization of the kynurenine pathway in human oligodendrocytes , 2007 .

[10]  G. M. Mackay,et al.  Altered kynurenine metabolism correlates with infarct volume in stroke , 2007, The European journal of neuroscience.

[11]  V. Karanikas,et al.  Tumor immune escape mediated by indoleamine 2,3-dioxygenase. , 2007, Immunology letters.

[12]  G. Prendergast,et al.  Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. , 2007, Cancer research.

[13]  L. Jermiin,et al.  Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. , 2007, Gene.

[14]  H. Steinbusch,et al.  Kynurenine pathway in major depression: evidence of impaired neuroprotection. , 2007, Journal of affective disorders.

[15]  János Kálmán,et al.  Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease , 2007, Neurochemistry International.

[16]  M. Gisslén,et al.  Acute psychotic symptoms in HIV-1 infected patients are associated with increased levels of kynurenic acid in cerebrospinal fluid , 2007, Brain, Behavior, and Immunity.

[17]  Adeeba Kamarulzaman,et al.  AIDS Res Hum Retroviruses , 2006 .

[18]  T. Stone,et al.  KYNURENINE PATHWAY METABOLISM IN PATIENTS WITH OSTEOPOROSIS AFTER 2 YEARS OF DRUG TREATMENT , 2006, Clinical and experimental pharmacology & physiology.

[19]  D. Nutt,et al.  Tryptophan metabolism in the central nervous system: medical implications , 2006, Expert Reviews in Molecular Medicine.

[20]  R. Schwarcz,et al.  Kynurenine Pathway Enzymes in Dendritic Cells Initiate Tolerogenesis in the Absence of Functional IDO1 , 2006, The Journal of Immunology.

[21]  D. Fuchs,et al.  Tryptophan degradation increases with stage in patients with rheumatoid arthritis , 2006, Clinical Rheumatology.

[22]  R. Scheyer,et al.  A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses , 2006, Neurology.

[23]  R. Rosenthal,et al.  Differential effects of the tryptophan metabolite3‐hydroxyanthranilic acid on the proliferation of human CD8+ T cells induced by TCR triggering or homeostatic cytokines , 2006, European journal of immunology.

[24]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with chronic brain injury , 2006, European journal of neurology.

[25]  V. Meininger,et al.  Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis , 2006, Neurodegenerative Diseases.

[26]  K. Blennow,et al.  Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia , 2005, Schizophrenia Research.

[27]  O. Takikawa Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. , 2005, Biochemical and biophysical research communications.

[28]  Michael Platten,et al.  Treatment of Autoimmune Neuroinflammation with a Synthetic Tryptophan Metabolite , 2005, Science.

[29]  D. Scheuner,et al.  ER stress‐regulated translation increases tolerance to extreme hypoxia and promotes tumor growth , 2005, The EMBO journal.

[30]  F. Tarantini,et al.  Kynurenic Acid Inhibits the Release of the Neurotrophic Fibroblast Growth Factor (FGF)-1 and Enhances Proliferation of Glia Cells, in vitro , 2005, Cellular and Molecular Neurobiology.

[31]  G. Smythe,et al.  Prolonged Survival of a Murine Model of Cerebral Malaria by Kynurenine Pathway Inhibition , 2005, Infection and Immunity.

[32]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[33]  D. Fuchs,et al.  Tryptophan degradation in patients with gynecological cancer correlates with immune activation. , 2005, Cancer letters.

[34]  F. Moroni,et al.  Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus , 2005, Neuropharmacology.

[35]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[36]  R. Schwarcz,et al.  Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum , 2005, Journal of neurochemistry.

[37]  B. Baban,et al.  GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. , 2005, Immunity.

[38]  F. Barkhof,et al.  Treatment with laquinimod reduces development of active MRI lesions in relapsing MS , 2005, Neurology.

[39]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[40]  K. Tracey,et al.  Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis , 2004, Nature Medicine.

[41]  G. Hedlund,et al.  Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats , 2004, Journal of Neuroimmunology.

[42]  D. Fuchs,et al.  Increasing production of homocysteine and neopterin and degradation of tryptophan with older age. , 2004, Clinical biochemistry.

[43]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[44]  B. Brew,et al.  A&bgr;1-42 induces production of quinolinic acid by human macrophages and microglia , 2003, Neuroreport.

[45]  T. Taylor,et al.  Metabolites of the kynurenine pathway of tryptophan metabolism in the cerebrospinal fluid of Malawian children with malaria. , 2003, The Journal of infectious diseases.

[46]  D. Fuchs,et al.  Immune activation and degradation of tryptophan in coronary heart disease , 2003, European journal of clinical investigation.

[47]  W. Turski,et al.  Endogenous protectant kynurenic acid in amyotrophic lateral sclerosis , 2003, Acta neurologica Scandinavica.

[48]  Peter A. Ward,et al.  Novel strategies for the treatment of sepsis , 2003, Nature Medicine.

[49]  D. Fuchs,et al.  Longitudinal study of tryptophan degradation during and after pregnancy. , 2003, Life sciences.

[50]  D. Munn,et al.  Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division , 2002, Immunology.

[51]  S. Pastorino,et al.  Antagonistic effect of picolinic acid and interferon-γ on macrophage inflammatory protein-1α/β production , 2002 .

[52]  G. Giovannoni,et al.  Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients , 2002, Neuroscience Letters.

[53]  U. Grohmann,et al.  T cell apoptosis by tryptophan catabolism , 2002, Cell Death and Differentiation.

[54]  W. Riedel,et al.  Tryptophan, mood, and cognitive function , 2002, Brain, Behavior, and Immunity.

[55]  D. Fuchs,et al.  Effective antiretroviral therapy reduces degradation of tryptophan in patients with HIV-1 infection. , 2002, Clinical immunology.

[56]  G. Hedlund,et al.  The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis , 2002, Journal of Neuroimmunology.

[57]  G. Damonte,et al.  Tryptophan-derived Catabolites Are Responsible for Inhibition of T and Natural Killer Cell Proliferation Induced by Indoleamine 2,3-Dioxygenase , 2002, The Journal of experimental medicine.

[58]  Gerhard Opelz,et al.  Inhibition of Allogeneic T Cell Proliferation by Indoleamine 2,3-Dioxygenase–expressing Dendritic Cells , 2002, The Journal of experimental medicine.

[59]  B. Brew,et al.  Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease , 2002, Redox report : communications in free radical research.

[60]  T. Stone,et al.  The pharmacological manipulation of glutamate receptors and neuroprotection. , 2002, European journal of pharmacology.

[61]  C. Harmer,et al.  Acute administration of citalopram facilitates memory consolidation in healthy volunteers , 2002, Psychopharmacology.

[62]  D. Fuchs,et al.  Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer , 2002, British Journal of Cancer.

[63]  B. Winblad,et al.  Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue , 2002, Neuropharmacology.

[64]  J. Farrar,et al.  The clinical significance of cerebrospinal fluid levels of kynurenine pathway metabolites and lactate in severe malaria. , 2002, The Journal of infectious diseases.

[65]  D. Fuchs,et al.  Increased neopterin production and tryptophan degradation in advanced Parkinson's disease , 2002, Journal of Neural Transmission.

[66]  K. Blennow,et al.  Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia , 2001, Neuroscience Letters.

[67]  P. Hamilton,et al.  Antiviral, cytotoxic and apoptotic activities of picolinic acid on human immunodeficiency virus-1 and human herpes simplex virus-2 infected cells. , 2001, Anticancer research.

[68]  M. Pericak-Vance,et al.  The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis , 2001, Nature Genetics.

[69]  R. Schwarcz,et al.  Increased cortical kynurenate content in schizophrenia , 2001, Biological Psychiatry.

[70]  R. Schwarcz,et al.  The Brain Metabolite Kynurenic Acid Inhibits α7 Nicotinic Receptor Activity and Increases Non-α7 Nicotinic Receptor Expression: Physiopathological Implications , 2001, The Journal of Neuroscience.

[71]  L. Ellerby,et al.  Coupling Endoplasmic Reticulum Stress to the Cell Death Program , 2001, The Journal of Biological Chemistry.

[72]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[73]  M. Seishima,et al.  Lipopolysaccharide induction of indoleamine 2,3‐dioxygenase is mediated dominantly by an IFN‐γ‐independent mechanism , 2001, European journal of immunology.

[74]  M. Murray,et al.  Increased plasma tryptophan in HIV-infected patients treated with pharmacologic doses of nicotinamide. , 2001, Nutrition.

[75]  M. Raiteri,et al.  Presynaptic kynurenate‐sensitive receptors inhibit glutamate release , 2001, The European journal of neuroscience.

[76]  D. Fuchs,et al.  Neopterin production and tryptophan degradation in humans infected by Streptococcus pyogenes , 2001, Medical Microbiology and Immunology.

[77]  L. Massacesi,et al.  Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis , 2001, Neuroscience.

[78]  B. Dubois,et al.  Outcome of patients with HIV-1-related cognitive impairment on highly active antiretroviral therapy , 2001, AIDS.

[79]  M. Altfeld,et al.  Parallel decrease in neurotoxin quinolinic acid and soluble tumor necrosis factor receptor p75 in serum during highly active antiretroviral therapy of HIV type 1 disease. , 2000, AIDS research and human retroviruses.

[80]  L. Chylack,et al.  3-Hydroxykynurenine and 3-hydroxyanthranilic acid generate hydrogen peroxide and promote alpha-crystallin cross-linking by metal ion reduction. , 2000, Biochemistry.

[81]  B. Brew,et al.  Characterisation of kynurenine pathway metabolism in human astrocytes and implications in neuropathogenesis , 2000, Redox report : communications in free radical research.

[82]  G. Melillo,et al.  The Tryptophan Catabolite Picolinic Acid Selectively Induces the Chemokines Macrophage Inflammatory Protein-1α and -1β in Macrophages1 , 2000, The Journal of Immunology.

[83]  R. Schwarcz,et al.  Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus. , 2000, European journal of pharmacology.

[84]  R. Appelberg,et al.  Macrophage Control of Mycobacterial Growth Induced by Picolinic Acid Is Dependent on Host Cell Apoptosis1 , 2000, The Journal of Immunology.

[85]  D. Munn,et al.  Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? , 1999, Immunology today.

[86]  A. Chiarugi,et al.  Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl) thiazol-2yl]-benzenesulfonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase , 1999, Neuropharmacology.

[87]  F. Moroni,et al.  Kynurenine Hydroxylase Inhibitors Reduce Ischemic Brain Damage: Studies with (m-Nitrobenzoyl)-Alanine (mNBA) and 3,4-Dimethoxy-[-N-4-(Nitrophenyl)Thiazol-2YL]-Benzenesulfonamide (Ro 61-8048) in Models of Focal or Global Brain Ischemia , 1999, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[88]  D. Munn,et al.  Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism , 1999, The Journal of experimental medicine.

[89]  M. Takemura,et al.  Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. , 1998, Archives of biochemistry and biophysics.

[90]  H. Gendelman,et al.  Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus-associated dementia. , 1998, The Journal of infectious diseases.

[91]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[92]  A. Lackner,et al.  Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[93]  R. Beninger,et al.  Modulation of striatal quinolinate neurotoxicity by elevation of endogenous brain kynurenic acid , 1998, British journal of pharmacology.

[94]  M. Gompels,et al.  Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. , 1998, Clinical chemistry.

[95]  F. Leblhuber,et al.  Activated Immune System in Patients with Huntington's Disease , 1998, Clinical Chemistry and Laboratory Medicine.

[96]  N. Yoshimura,et al.  Tranilast inhibits the proliferation, chemotaxis and tube formation of human microvascular endothelial cells in vitro and angiogenesis in vivo , 1997, British journal of pharmacology.

[97]  E. Major,et al.  Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. , 1997, The Biochemical journal.

[98]  J. Moffett,et al.  Quinolinate Immunoreactivity in Experimental Rat Brain Tumors Is Present in Macrophages but Not in Astrocytes , 1997, Experimental Neurology.

[99]  J. Tenu,et al.  Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. , 1997, Archives of biochemistry and biophysics.

[100]  R. Schwarcz,et al.  Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo. , 1997, European journal of pharmacology.

[101]  R. Schwarcz,et al.  Facilitated brain uptake of 4‐chlorokynurenine and conversion to 7‐chlorokynurenic acid , 1996, Neuroreport.

[102]  S. Steinberg,et al.  Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis, and adult T-cell leukemia/lymphoma. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[103]  C. Broder,et al.  CC CKR5: A RANTES, MIP-1α, MIP-1ॆ Receptor as a Fusion Cofactor for Macrophage-Tropic HIV-1 , 1996, Science.

[104]  A. Saah,et al.  Effects of micronutrient intake on survival in human immunodeficiency virus type 1 infection. , 1996, American journal of epidemiology.

[105]  J. Moffett,et al.  Localization of quinolinic acid in the murine AIDS model of retrovirus-induced immunodeficiency: implications for neurotoxicity and dendritic cell immunopathogenesis , 1996, AIDS.

[106]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[107]  S. Schiff,et al.  Quinolinic acid in tumors, hemorrhage and bacterial infections of the central nervous system in children , 1995, Journal of the Neurological Sciences.

[108]  P. Morand,et al.  Dihydroorotate Dehydrogenase Is a High Affinity Binding Protein for A77 1726 and Mediator of a Range of Biological Effects of the Immunomodulatory Compound (*) , 1995, The Journal of Biological Chemistry.

[109]  A. Chiarugi,et al.  Comparison of the Neurochemical and Behavioral Effects Resulting from the Inhibition of Kynurenine Hydroxylase and/or Kynureninase , 1995, Journal of neurochemistry.

[110]  M. Demitrack,et al.  Cerebrospinal fluid levels of kynurenine pathway metabolites in patients with eating disorders: Relation to clinical and biochemical variable , 1995, Biological Psychiatry.

[111]  K. Orita,et al.  Decreased serum tryptophan in patients with cancer cachexia correlates with increased serum neopterin. , 1995, Immunological investigations.

[112]  O. H. Viveros,et al.  Neurotoxin Quinolinic Acid Is Selectively Elevated in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis , 1995, Journal of neurochemistry.

[113]  G. Reynolds,et al.  Increased Concentrations of the Neurotoxin 3‐Hydroxykynurenine in the Frontal Cortex of HIV‐1‐Positive Patients , 1995, Journal of neurochemistry.

[114]  H. Meltzer,et al.  Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: Further evidence for an immune response , 1994, Psychiatry Research.

[115]  D. Fuchs,et al.  Tryptophan concentrations increase in cerebrospinal fluid and blood after zidovudine treatment in patients with HIV type 1 infection. , 1994, AIDS research and human retroviruses.

[116]  R. Beninger,et al.  Picolinic acid blocks the neurotoxic but not the neuroexcitant properties of quinolinic acid in the rat brain: Evidence from turning behaviour and tyrosine hydroxylase immunohistochemistry , 1994, Neuroscience.

[117]  A. B. Orlikov,et al.  Kynurenine in blood plasma and DST in patients with endogenous anxiety and endogenous depression , 1994, Biological Psychiatry.

[118]  G. Lombardi,et al.  Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities , 1994, Neuroscience.

[119]  G. Melillo,et al.  Regulation of nitric-oxide synthase mRNA expression by interferon-gamma and picolinic acid. , 1994, The Journal of biological chemistry.

[120]  G. Costantino,et al.  Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase. , 1994, Journal of medicinal chemistry.

[121]  O. Devinsky,et al.  Kynurenine Pathway Metabolites in Cerebrospinal Fluid and Serum in Complex Partial Seizures , 1994, Epilepsia.

[122]  R. Beninger,et al.  Picolinic acid modulates kainic acid-evoked glutamate release from the striatum in vitro , 1993, Brain Research.

[123]  F. Bistoni,et al.  Protective effect of picolinic acid on mice intracerebrally infected with lethal doses of Candida albicans , 1993, Antimicrobial Agents and Chemotherapy.

[124]  J. Moffett,et al.  Antibodies to quinolinic acid reveal localization in select immune cells rather than neurons or astroglia , 1993, Brain Research.

[125]  T. Stone,et al.  Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.

[126]  I. Hertz-Picciotto,et al.  A prospective study of dietary intake and acquired immune deficiency syndrome in HIV-seropositive homosexual men. , 1993, Journal of acquired immune deficiency syndromes.

[127]  A. Koda,et al.  The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. , 1993, Japanese journal of pharmacology.

[128]  P. Wood,et al.  Indole-2-carboxylates, novel antagonists of the N-methyl-D-aspartate (NMDA)-associated glycine recognition sites: In vivo characterization , 1993, Neuropharmacology.

[129]  R. Beninger,et al.  Action of picolinic acid and structurally related pyridine carboxylic acids on quinolinic acid-induced cortical cholinergic damage , 1992, Brain Research.

[130]  G. Lombardi,et al.  Nicotinylalanine Increases the Formation of Kynurenic Acid in the Brain and Antagonizes Convulsions , 1992, Journal of neurochemistry.

[131]  M. Demitrack,et al.  Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.

[132]  G. Reynolds,et al.  Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease , 1992, Neuroscience Letters.

[133]  E. Major,et al.  Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.

[134]  M. Brodie,et al.  Nicotinylalanine increases cerebral kynurenic acid content and has anticonvulsant activity. , 1992, General Pharmacology.

[135]  Elsdon Storey,et al.  Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex , 1992, Journal of the Neurological Sciences.

[136]  A. Grace Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.

[137]  L. Varesio,et al.  IL-4 inhibits the costimulatory activity of IL-2 or picolinic acid but not of lipopolysaccharide on IFN-gamma-treated macrophages. , 1991, Journal of immunology.

[138]  R. S. Smith The macrophage theory of depression. , 1991, Medical hypotheses.

[139]  E. Werner,et al.  Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. , 1991, Immunology letters.

[140]  F. Ceci,et al.  Increased plasma free tryptophan levels in human cancer: a tumor related effect? , 1991, Anticancer research.

[141]  S. Baig,et al.  High performance liquid chromatography as a tool in the definition of abnormalities in monoamine and tryptophan metabolites in cerebrospinal fluid from patients with neurological disorders. , 1991, Biomedical chromatography : BMC.

[142]  J. Sidtis,et al.  Quinolinic acid in cerebrospinal fluid and serum in HIV‐1 Infection: Relationship to clinical and neurological status , 1991, Annals of neurology.

[143]  D. Radzioch,et al.  Picolinic acid, a catabolite of tryptophan, as the second signal in the activation of IFN-gamma-primed macrophages. , 1990, Journal of immunology.

[144]  S. Gupta,et al.  Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. , 1990, The Journal of biological chemistry.

[145]  R. Beninger,et al.  Quinolinate-induced cortical cholinergic damage: modulation by tryptophan metabolites , 1990, Brain Research.

[146]  M. Beal,et al.  Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.

[147]  W. Katon,et al.  Depression and chronic medical illness. , 1990, The Journal of clinical psychiatry.

[148]  H. Monyer,et al.  7‐Chlorokynurenate Blocks NMDA Receptor‐Mediated Neurotoxicity in Murine Cortical Culture , 1990, The European journal of neuroscience.

[149]  R. Stocker,et al.  Antioxidant activities of some tryptophan metabolites: possible implication for inflammatory diseases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[150]  A. Foster,et al.  Protection Against N‐methyl‐D‐aspartate Receptor‐Mediated Neuronal Degeneration In Rat Brain by 7‐chlorokynurenate and 3‐amino‐1‐hydroxypyrrolid‐2‐one, Antagonists at The Allosteric Site for Glycine , 1990, The European journal of neuroscience.

[151]  G. Norkrans,et al.  Indole amine deficiency in blood and cerebrospinal fluid from patients with human immunodeficiency virus infection , 1989, Journal of neuroscience research.

[152]  E. Werner,et al.  Characteristics of interferon induced tryptophan metabolism in human cells in vitro. , 1989, Biochimica et biophysica acta.

[153]  R. Schwarcz,et al.  Prolonged exposure to submicromolar concentrations of quinolinic acid causes excitotoxic damage in organotypic cultures of rat corticostriatal system , 1989, Neuroscience Letters.

[154]  G. Lombardi,et al.  Presence of Kynurenic Acid in the Mammalian Brain , 1988, Journal of neurochemistry.

[155]  E. Werner,et al.  Tryptophan degradation in patients infected by human immunodeficiency virus. , 1988, Biological chemistry Hoppe-Seyler.

[156]  D. Choi,et al.  Quinolinate neurotoxicity in cortical cell culture , 1987, Neuroscience.

[157]  O. Hayaishi,et al.  Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[158]  W. Pardridge,et al.  Neutral amino acid transport at the human blood-brain barrier. , 1986, Federation proceedings.

[159]  B. Beutler,et al.  Identity of tumour necrosis factor and the macrophage-secreted factor cachectin , 1985, Nature.

[160]  M. Salter,et al.  The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. , 1985, The Biochemical journal.

[161]  E. Pfefferkorn Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[162]  M. Cuénod,et al.  Identification of quinolinic acid in rat and human brain tissue , 1983, Neuroscience Letters.

[163]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[164]  T. Stone,et al.  An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid , 1982, Brain Research.

[165]  T. Stone,et al.  Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.

[166]  G. S. Johnson,et al.  Control of growth by picolinic acid: differential response of normal and transformed cells. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[167]  C. Pierce,et al.  Development of primary M, G, and A anti-TNP plaque-forming cell responses in vitro. , 1973, Journal of immunology.

[168]  R. McMenamy Binding of indole analogues to human serum albumin. Effects of fatty acids. , 1965, The Journal of biological chemistry.

[169]  B. Brew,et al.  Involvement of quinolinic acid in aids dementia complex , 2009, Neurotoxicity Research.

[170]  W J Riedel,et al.  Serotonin and human cognitive performance. , 2006, Current pharmaceutical design.

[171]  S. Gauthier,et al.  Studies on kynurenine in human cerebrospinal fluid: Lowered levels in epilepsy , 2005, Journal of Neural Transmission.

[172]  R. Beninger,et al.  Role of zinc in blockade of excitotoxic action of quinolinic acid by picolinic acid , 2005, Amino Acids.

[173]  M. Maes,et al.  IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity , 2005, Molecular Psychiatry.

[174]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[175]  D. Fuchs,et al.  Weight loss in patients with hematological neoplasias is associated with immune system stimulation , 2004, The clinical investigator.

[176]  Weimin Hu,et al.  Augmented inhibition of Candida albicans growth by murine neutrophils in the presence of a tryptophan metabolite, picolinic acid , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[177]  U. Grohmann,et al.  T cell apoptosis by kynurenines. , 2003, Advances in experimental medicine and biology.

[178]  B. Brew,et al.  Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.

[179]  S. Pastorino,et al.  Antagonistic effect of picolinic acid and interferon-gamma on macrophage inflammatory protein-1alpha/beta production. , 2002, Cellular immunology.

[180]  R. Schwarcz,et al.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[181]  S. Erhardt,et al.  Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons , 2001, Amino Acids.

[182]  森田 敏子 3-Hydroxyanthranilic acid,an L-tryptophan metabolite,induces apoptosis in monocyte-derived cells stimulated by interferon-γ , 2001 .

[183]  H. Scharfman,et al.  Electrophysiological effects of exogenous and endogenous kynurenic acid in the rat brain: studies in vivo and in vitro , 2000, Amino Acids.

[184]  H. Budka,et al.  Kynurenic acid metabolism in the brain of HIV-1 infected patients , 2000, Journal of Neural Transmission.

[185]  D. Fuchs,et al.  Tryptophan degradation and immune activation in Alzheimer's disease , 2000, Journal of Neural Transmission.

[186]  G. Melillo,et al.  The tryptophan catabolite picolinic acid selectively induces the chemokines macrophage inflammatory protein-1 alpha and -1 beta in macrophages. , 2000, Journal of immunology.

[187]  W. Riedel,et al.  Tryptophan depletion in normal volunteers produces selective impairment in memory consolidation , 1999, Psychopharmacology.

[188]  C. Broder,et al.  CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. , 1996, Science.

[189]  J. Corbeil,et al.  Quinolinic acid production is related to macrophage tropic isolates of HIV-1. , 1995, Journal of neurovirology.

[190]  E. Borden,et al.  Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. , 1991, Advances in experimental medicine and biology.

[191]  C. Nathan,et al.  Role of nitric oxide synthesis in macrophage antimicrobial activity. , 1991, Current opinion in immunology.

[192]  D. Rubinow,et al.  Cerebrospinal fluid quinolinic acid concentrations are increased in acquired immune deficiency syndrome. , 1989, Annals of neurology.

[193]  L. Varesio,et al.  Antiproliferative activity of picolinic acid due to macrophage activation. , 1987, Drugs under experimental and clinical research.